What the BMJ and clinical research say about Mounjaro

What peer-reviewed research has actually found, and where the BMJ fits in

The BMJ has published commentary, editorials and rapid responses on tirzepatide since the SURMOUNT programme produced its headline results. Those pieces broadly reflect what regulators and NICE concluded: the evidence base is substantial, the weight-loss outcomes are larger than those seen with earlier GLP-1 medicines, and questions remain around long-term cardiovascular outcomes, the right duration of treatment, and what happens when people stop.

The cornerstone trial most cited across the literature is SURMOUNT-1, which enrolled thousands of adults with obesity and no diabetes and followed them for 72 weeks. Average body-weight reduction reached around 20–21% at the 15 mg dose. Those are not cherry-picked figures; they are the pre-specified primary outcomes, published in the New England Journal of Medicine. The BMJ's commentary on such results has generally asked the right clinical questions: how much of the loss is fat versus lean mass, what the responder rates look like, and how outcomes differ across populations with different comorbidities.

A common misconception is that weight-loss percentages in trials translate directly to real-world outcomes for everyone. They represent averages across large, diverse groups under controlled conditions, individual results vary, and the prescriber's job is partly to help you understand what a realistic outcome looks like for your starting point.

For a fuller picture of tirzepatide as a medicine, the tirzepatide overview covers the mechanism, the licensed strengths and the trial programme in plain language. You can also read NICE's appraisal of tirzepatide (TA1026), which summarises the clinical evidence NICE considered before recommending the medicine.

The SURMOUNT-5 comparison, what the head-to-head data means for your choice

For many people reading BMJ coverage of Mounjaro, the real question is simpler: how does it compare to Wegovy (semaglutide 2.4 mg), which was the standard-of-care injectable weight-loss treatment before tirzepatide arrived?

SURMOUNT-5 answered that directly. Published in the New England Journal of Medicine in 2025 and involving 751 adults with obesity but without diabetes over 72 weeks, it was an open-label head-to-head trial. Tirzepatide produced greater average weight reduction than semaglutide 2.4 mg. That result informed NICE's discussion in TA1026, which noted that indirect comparisons across the trial programmes also favoured tirzepatide.

This does not make tirzepatide the automatic right choice for every person. Tolerability, contraindications, injection preference, whether the newer higher-dose semaglutide options close the gap, and individual health history all matter. The clinical perspective on Mounjaro explores how prescribers weigh these factors. For those who prefer to understand cost alongside clinical value before booking a consultation, the Mounjaro UK cost and access guide is a useful companion read.

What the literature is clear about is that this is not a decision to make based on social media posts or forum recommendations. A prescriber who can review your medical history, current medicines and weight-related conditions is the right person to translate trial averages into an individual recommendation.

What the evidence says about who this medicine is licensed for

Published commentary in outlets including the BMJ has focused attention on eligibility: who the trials enrolled, who NICE recommends the medicine for, and where private prescribing fills a gap.

The licensed indication in the UK covers adults with a BMI of 30 or above, or 27 or above where at least one weight-related condition is present, such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. NICE's recommendation through TA1026 is more selective: it requires a BMI of 35 or above plus at least one weight-related comorbidity for NHS access, and the phased rollout means many people who are clinically eligible still face a wait.

Private prescribing through a regulated pharmacy operates within the licensed indication. The prescriber still assesses the whole picture, BMI alone is not sufficient. You can check the current eligibility framework and the NHS rollout timetable on the Mounjaro hub, or explore the weight-loss treatment overview if you are still deciding between available options.

One thing the evidence cannot do is replace that clinical conversation. Trials tell us what happened on average; a prescriber tells you what is appropriate for you specifically.

Side effects, safety signals and what to watch for

Peer-reviewed coverage of tirzepatide, including BMJ correspondence, has examined the safety data alongside the efficacy results. The profile that emerges is consistent across SURMOUNT trials: gastrointestinal effects are the most common, particularly nausea, vomiting, diarrhoea and constipation. These are most noticeable in the early weeks and typically reduce as the body adjusts. Dose titration (starting at 2.5 mg and increasing gradually, with Mounjaro 2.5 mg being the starting dose before any upward adjustment) exists precisely to give your system time to settle before the dose rises further.

The MHRA monitors tirzepatide under its Black Triangle scheme, which means enhanced surveillance continues as real-world use grows. The January 2026 MHRA Drug Safety Update for GLP-1 medicines highlighted acute pancreatitis as a known, infrequent but potentially serious effect: severe stomach pain that persists and may spread to the back warrants urgent medical attention. You can report any suspected side effect through the MHRA Yellow Card scheme.

The Mounjaro side effects guide covers this territory in detail, including how to tell expected adjustment from something that needs prompt review. People with a history of medullary thyroid carcinoma, MEN2, pancreatitis, or certain gastrointestinal conditions should discuss those histories with a prescriber before starting. The same applies to anyone who is pregnant, trying to conceive, or breastfeeding, tirzepatide is not recommended in those situations.

If you would like a prescriber to review your specific health history, you can start your free consultation at any point. The review is carried out the same day by a real clinician, not automated software, and there is no obligation to proceed.